Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?
Groetzner
J
J
Department of Cardiac Surgery, Ludwig Maximilian University Munich, Grosshadern Medical Center, Munich, Germany.
Meiser
B M
BM
Schirmer
J
J
Koglin
J
J
vScheidt
W
W
Klauss
V
V
Cremer
P
P
Reichenspurner
H
H
Reichart
B
B
D000328:Adult; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D007674:Kidney Diseases / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus